Single Domain Antibody Discovery Services

20+ projects delivered,100% success rate

Large size of naïve library(5.05x10¹⁰) with high quality

The Status of sdAb as Therapeutics

sdAb is a promising next-generation therapeutic antibody technology for cancer immunotherapy and other applications.

• 
• • Efficacy and safety validated in clinical studies
  • Easy to modify for specific applications
  • Relative-short discovery cycle
  • Pursued by main-stream pharmaceutical companies
  • Cost-effective in manufacturing

SdAb Discovery Service Workflow

• SdAb Naïve Library Service
  
• SdAb Immunized Library Service
  

Service highlights

SdAb Immune Library

• Using non-immunized Alpaca/Llama for each project
• 20+ projects delivered, 100% success rate

SdAb Naïve Library

• Library Size: 5.05*10¹⁰ ( 100 donors )
• Quality of Library
  • In frame rate/ORF rate: >95%
  • Diversity: Normal Distribution of CDR3 diversity
• As fast as 2 weeks to deliver single domain antibody sequences

Diversified panning & screening strategies to ensure diversity & affinity

• Panning:
  • Solid panning, liquid panning, cell panning, combination panning, competitive panning tailored to different type of targets
  • Up to 2 panning strategies are used to maximize the success rate
  • No more than 3-round panning to retain the sequence diversity
• Screening:
  • FASEBA HTP screening combined with ELISA/FACS binding and SPR affinity ranking

Single Domain Antibody leads with high affinity (10^-9~10^-10 or better) generated in case study